NuScale Stock Plunge: Project Delays Spark 26% Drop
💡 Key Takeaway
NuScale faces critical project delays, massive cash burn, and shareholder exits that threaten its commercialization timeline.
What Went Wrong in February
NuScale Power's stock collapsed 26.5% in February, erasing all its January gains and leaving shares down nearly 18% for the year. The decline was driven by multiple negative developments that shook investor confidence.
A TD Cowen analyst downgraded the stock from buy to hold, warning that NuScale's flagship project in Romania could be delayed until 2034. This represents a four-year delay from the original 2029-2030 target for the VOYGR small modular reactor plant.
Compounding the problem, Fluor—NuScale's largest shareholder and engineering partner—continued selling its stake, offloading 71 million shares in February alone. Fluor plans to exit NuScale completely by Q2 2026.
The company's Q4 earnings revealed a stunning $507.4 million milestone payment to partner ENTRA1 Energy, recognized as an expense despite NuScale not having built any operational plants. This contributed to an operating loss of nearly $690 million for 2025.
Why This Matters for Investors
The Romania delay isn't just a timeline shift—it threatens NuScale's entire business model. With RoPower as its only customer, any project slippage directly impacts revenue projections and cash flow timing.
The massive $507 million payment raises serious questions about capital allocation. Recognizing such a large expense before generating meaningful revenue suggests the path to profitability is longer and riskier than investors anticipated.
Fluor's exit signals deteriorating confidence from a key strategic partner. As an engineering giant, Fluor's departure removes technical expertise and market credibility that NuScale desperately needs.
Multiple analyst price target cuts and investor lawsuits alleging misrepresentation create additional headwinds. The legal challenges could distract management and potentially result in financial settlements.
Small modular reactors have compelling advantages over traditional nuclear plants, but NuScale's execution challenges highlight the risks of investing in pre-commercialization technology companies.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Avoid SMR until the company demonstrates credible progress toward commercialization.
The combination of project delays, massive cash burn, and key partner exits creates too much uncertainty. While SMR technology has long-term potential, NuScale's execution risks outweigh the opportunity at current levels.
What This Means for Me
